DE69133074D1 - Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten - Google Patents

Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten

Info

Publication number
DE69133074D1
DE69133074D1 DE69133074T DE69133074T DE69133074D1 DE 69133074 D1 DE69133074 D1 DE 69133074D1 DE 69133074 T DE69133074 T DE 69133074T DE 69133074 T DE69133074 T DE 69133074T DE 69133074 D1 DE69133074 D1 DE 69133074D1
Authority
DE
Germany
Prior art keywords
agent
growth factor
fibroblast growth
basic fibroblast
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69133074T
Other languages
English (en)
Other versions
DE69133074T2 (de
Inventor
Keigo Hanada
Yoshiyuki Hiyama
Makoto Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69133074D1 publication Critical patent/DE69133074D1/de
Publication of DE69133074T2 publication Critical patent/DE69133074T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69133074T 1990-12-19 1991-12-17 Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten Expired - Fee Related DE69133074T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP41916890 1990-12-19
JP03152517A JP3135138B2 (ja) 1990-12-19 1991-05-28 骨疾患治療剤

Publications (2)

Publication Number Publication Date
DE69133074D1 true DE69133074D1 (de) 2002-08-29
DE69133074T2 DE69133074T2 (de) 2002-12-12

Family

ID=26481415

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133074T Expired - Fee Related DE69133074T2 (de) 1990-12-19 1991-12-17 Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten

Country Status (5)

Country Link
EP (1) EP0493737B1 (de)
JP (1) JP3135138B2 (de)
AT (1) ATE220915T1 (de)
DE (1) DE69133074T2 (de)
ES (1) ES2180527T3 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3639593B2 (ja) 1993-05-31 2005-04-20 科研製薬株式会社 塩基性線維芽細胞増殖因子含有架橋ゼラチンゲル製剤
WO1995005840A1 (fr) * 1993-08-25 1995-03-02 Kaken Pharmaceutical Co., Ltd. Remede contre les affections periodontiques
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
EP1218026B1 (de) 1999-09-30 2004-03-31 Kaken Pharmaceutical Co., Ltd. Herstellung eines medikamentes zur verbesserten heilung des sternums nach einer sternotomie
AU2003244459A1 (en) * 2002-02-04 2003-09-02 Koken Co., Ltd. Preparations for treating bone fracture or bone loss or elevating bone density
WO2003106663A1 (ja) 2002-06-18 2003-12-24 エーザイ株式会社 遺伝子治療用初代培養脂肪細胞
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222602T1 (de) * 1985-09-12 2002-09-15 Scios Inc Rekombinante fibroblasten-wachstums-faktoren
JPH02504468A (ja) * 1987-11-24 1990-12-20 アムジエン・インコーポレーテツド 繊維芽細胞成長因子のアナログ
GB8821795D0 (en) * 1988-09-16 1988-10-19 Erba Carlo Spa New derivatives of human/bovine basic fibroplast growth factor
ATE141643T1 (de) * 1988-11-04 1996-09-15 Chiron Corp Expression und prozessierung von acetylierten fgfs in hefen
FR2642086B1 (fr) * 1989-01-26 1992-09-04 Sanofi Sa Gene recombinant codant pour un facteur basique de croissance des fibroblastes et ledit facteur

Also Published As

Publication number Publication date
JP3135138B2 (ja) 2001-02-13
EP0493737A1 (de) 1992-07-08
DE69133074T2 (de) 2002-12-12
JPH05124975A (ja) 1993-05-21
EP0493737B1 (de) 2002-07-24
EP0493737A3 (de) 1992-12-30
ATE220915T1 (de) 2002-08-15
ES2180527T3 (es) 2003-02-16

Similar Documents

Publication Publication Date Title
DE69634748D1 (de) Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
DE69533176D1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69031939D1 (de) Osteoinduktive zusammensetzungen
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE69021133T2 (de) Intramedullar-Nagel mit selbstverriegelbarem Ende zur Behandlung von metadiaphysialen Brüchen langer Knochen.
ATE71629T1 (de) Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
ATE67094T1 (de) Knochenzement.
DE69133074T2 (de) Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
ATE195424T1 (de) Verfahren zur verbesserung der wundheilung und gewebeerneuerung
ATE193450T1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenbrüchen
DK0585801T3 (da) Konoglerelateret protein af cadherin-typen og fremgangsmåde til dets fremstilling
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE69915852D1 (de) Lhrh-analoga zur behandlung der osteoporose
DE69523250T2 (de) Verwendung von Osteoblast-Proliferationsfaktor
DE69022027D1 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee